

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 4 MAY 10 CA/CAplus enhanced with 1900-1906 U.S. patent records  
NEWS 5 MAY 11 KOREAPAT updates resume  
NEWS 6 MAY 19 Derwent World Patents Index to be reloaded and enhanced  
NEWS 7 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2  
NEWS 8 MAY 30 The F-Term thesaurus is now available in CA/CAplus  
NEWS 9 JUN 02 The first reclassification of IPC codes now complete in INPADOC  
NEWS 10 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and and display fields  
NEWS 11 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL  
NEWS 12 JUL 11 CHEMSAFE reloaded and enhanced  
NEWS 13 JUL 14 FSTA enhanced with Japanese patents  
NEWS 14 JUL 19 Coverage of Research Disclosure reinstated in DWPI  
NEWS 15 AUG 09 INSPEC enhanced with 1898-1968 archive  
NEWS 16 AUG 28 ADISCTI Reloaded and Enhanced  
NEWS 17 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes  
NEWS 18 SEP 11 CA/CAplus enhanced with more pre-1907 records  
  
NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* \* \* \* \* STN Columbus \* \* \* \* \* \* \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:38:46 ON 12 SEP 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
------------------	---------------

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 09:39:08 ON 12 SEP 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 SEP 2006 HIGHEST RN 906423-10-7  
DICTIONARY FILE UPDATES: 11 SEP 2006 HIGHEST RN 906423-10-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10534741.str



chain nodes :

10 22

ring nodes :

1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 18 19

chain bonds :

1-10 10-15 12-22

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 11-15 11-12 12-13 13-14 13-16  
14-15 14-19 16-17 17-18 18-19

exact/norm bonds :

1-2 1-6 1-10 2-3 3-4 4-5 5-6 5-7 6-9 8-9 10-15

exact bonds :

7-8 11-15 11-12 12-13 12-22 14-15


normalized bonds :  
13-14 13-16 14-19 16-17 17-18 18-19  
isolated ring systems :  
containing 1 : 11 :

G1:O,N

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom  
22:CLASS

L1 STRUCTURE UPLOADED

=> d 11  
L1 HAS NO ANSWERS  
L1 STR



G1 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s 11  
SAMPLE SEARCH INITIATED 09:39:32 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE  
  
100.0% PROCESSED 5 ITERATIONS 4 ANSWERS  
SEARCH TIME: 00.00.01  
  
FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
                          BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 5 TO 234  
PROJECTED ANSWERS: 4 TO 200

L2 4 SEA SSS SAM L1

=> s 11 full  
FULL SEARCH INITIATED 09:39:37 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 153 TO ITERATE

100.0% PROCESSED 153 ITERATIONS 131 ANSWERS  
SEARCH TIME: 00.00.01

L3 131 SEA SSS FUL L1

=> file caplus		SINCE FILE	TOTAL
COST IN U.S. DOLLARS		ENTRY	SESSION
FULL ESTIMATED COST		166.94	167.15

FILE 'CAPLUS' ENTERED AT 09:39:42 ON 12 SEP 2006  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Sep 2006 VOL 145 ISS 12  
 FILE LAST UPDATED: 11 Sep 2006 (20060911/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>


=> s 13 full  
 L4 5 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2004:453215 CAPLUS  
 DOCUMENT NUMBER: 141:7116  
 TITLE: Preparation of 8-substituted imidazopyridines as gastric secretion inhibitors  
 INVENTOR(S): Simon, Wolfgang-Alexander; Postius, Stefan; Kromer, Wolfgang; Buhr, Wilm; Senn-Bilfinger, Joerg; Zimmermann, Peter Jan  
 PATENT ASSIGNEE(S): Altana Pharma Ag, Germany  
 SOURCE: PCT Int. Appl., 37 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004046144	A1	20040603	WO 2003-EP12787	20031115
W: AE, AL, AU, BA, BR, CA, CN, CO, DZ, EC, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2506027	AA	20040603	CA 2003-2506027	20031115
AU 2003288071	A1	20040615	AU 2003-288071	20031115
EP 1565465	A1	20050824	EP 2003-779937	20031115

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 BR 2003016201 A 20051004 BR 2003-16201 20031115  
 CN 1708497 A 20051214 CN 2003-80102585 20031115  
 JP 2006508142 T2 20060309 JP 2004-552614 20031115  
 US 2006100234 A1 20060511 US 2005-534741 20050512  
 NO 2005002857 A 20050613 NO 2005-2857 20050613  
 PRIORITY APPLN. INFO.: EP 2002-25866 A 20021119  
 OTHER SOURCE(S): MARPAT 141:7116 W 20031115  
 GI



**AB** 8-Substituted imidazopyridines of formula I [R1 = H, alkyl, cycloalkyl, alkoxy, etc.; R2 = H, alkyl, aryl, cycloalkyl, halo, etc.; R3, R4 = H, halo, alkyl, carboxy, alkoxy carbonyl, etc.; R5 = H, alkyl, alkoxy, OH, nitro, (substituted) amino, etc.; R6 = H, alkyl, alkoxy, alkoxy carbonyl, etc.; X = O, NH; Z = (substituted) CH2, (substituted) CH2CH2] are prepared. The compds. have gastric secretion inhibiting and excellent gastric and intestinal protective action properties. Thus, II was prepared from Et 2,3-dimethyl-8-(benzyloxy)imidazo[1,2-a]pyridine-6-carboxylate, 1,2-epoxyindane and dimethylamine. II had >30% inhibition of acid secretion in perfused rat stomach at 1  $\mu\text{mol}/\text{kg}$  i.d.

**IT**  
 697254-99-2P 697255-01-9P 697255-03-1P  
 697255-05-3P 697255-10-0P 697255-14-4P  
 697255-16-6P 697255-17-7P 697255-18-8P  
 697255-19-9P


**RL:** PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazopyridines as gastric secretion inhibitors)

**RN** 697254-99-2 CAPLUS

**CN** Imidazo[1,2-a]pyridine-6-carboxamide, 8-[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-N-(2-methoxyethyl)-2,3-dimethyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 697255-01-9 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-N,N,2,3-tetramethyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 697255-03-1 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-N,2,3-trimethyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 697255-05-3 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-2,3-dimethyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 697255-10-0 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]oxy]-N,N,2,3-tetramethyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 697255-14-4 CAPLUS

CN 1H-Inden-2-ol, 2,3-dihydro-1-[(6-(methoxymethyl)-2,3-dimethylimidazo[1,2-a]pyridin-8-yl)oxy]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 697255-16-6 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[(1S,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]oxy]-N,N,2,3-tetramethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 697255-17-7 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, N,N,2,3-tetramethyl-8-[(1R,2R)-1,2,3,4-tetrahydro-2-hydroxy-1-naphthalenyl]oxy]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 697255-18-8 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[(1R,2R)-2,3-dihydro-2-hydroxy-7-methoxy-1H-inden-1-yl]oxy]-N,N,2,3-tetramethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 697255-19-9 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[(1R,2R)-2,3-dihydro-2-hydroxy-7-

methyl-1H-inden-1-yl]oxy]-N,N,2,3-tetramethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 697254-95-8P 697254-97-0P 697255-08-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of imidazopyridines as gastric secretion inhibitors)

RN 697254-95-8 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxylic acid, 8-[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-2,3-dimethyl-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 697254-97-0 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxylic acid, 8-[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-2,3-dimethyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 697255-08-6 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxylic acid, 8-[[<sup>1</sup>(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]oxy]-2,3-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1990:591349 CAPLUS

DOCUMENT NUMBER: 113:191349

TITLE: Preparation of 8-(indenyl)imidazo[1,2-a]pyridines and analogs as gastrointestinal agents

INVENTOR(S): Rainer, Georg; Schaefer, Hartmann; Senn-Bilfinger, Joerg; Grundler, Gerhard; Klemm, Kurt; Simon, Wolfgang Alexander; Riedel, Richard; Postius, Stefan

PATENT ASSIGNEE(S): Byk-Gulden Lomberg Chemische Fabrik G.m.b.H., Germany

SOURCE: Eur. Pat. Appl., 26 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 368158 R: ES, GR	A1	19900516	EP 1989-120355	19891103
WO 9005136 W: AU, DK, FI, HU, JP, KR, NO, US RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE	A1	19900517	WO 1989-EP1316	19891103
AU 8946347	A1	19900528	AU 1989-46347 CH 1988-4120	19891103 A 19881107
PRIORITY APPLN. INFO.:			WO 1989-EP1316	A 19891103

OTHER SOURCE(S): MARPAT 113:191349

GI For diagram(s), see printed CA Issue.

AB The title compds. [I; R = benzocycloalkyl group Q1; G = CH(OR<sub>5</sub>)CH<sub>2</sub>CH<sub>2</sub>,

CH2CH(OR5)CHMe, CH2CH(OR5)CH2CH, etc.; R1 = H, (hydroxy)alkyl, haloalkyl, cyanoalkyl, alkoxy carbonyl; R2 = H, (hydroxy)alkyl, haloalkyl, cyanoalkyl, CHO, dialkylaminoalkyl; R3, R4 = H, alkoxy, halo; R5 = alkyl, alkanoyl, carbamoyl, etc.] were prepared. Thus, I (R = H, R1 = Me, R2 = CHO) was stirred 14 h at 40° with 5-fluoroindene 1,2-oxide in aqueous MeOH containing Et<sub>3</sub>N to give I (R = trans-indanyl group Q2, R1 = Me, R2 = CHO, R5 = H) which was stirred 3 h with MeOCH<sub>2</sub>COCl in pyridine containing 4-dimethylamino-pyridine to give I (R = trans-indanyl group Q2, R1 = Me, R2 = CHO, R5 = COCH<sub>2</sub>OMe). The latter was stirred with NaBH<sub>4</sub> in aqueous MeOH to give I (R = trans-indanyl group Q2, R1 = Me, R2 = CH<sub>2</sub>OH, R5 = COCH<sub>2</sub>OMe) which had ED<sub>50</sub> of 0.8 μ mol/kg i.v. against pentagastrin-stimulated gastric acid secretion in rats.

IT 121081-93-4P 121098-85-9P 130014-58-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of gastrointestinal agents)

RN 121081-93-4 CAPLUS

CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121098-85-9 CAPLUS

CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[(5-fluoro-2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 130014-58-3 CAPLUS

CN Carbonochloridic acid, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, monohydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl


IT 129988-57-4P 129988-58-5P 129988-59-6P  
 129988-60-9P 129988-61-0P 129988-62-1P  
 129988-63-2P 129988-64-3P 129988-65-4P  
 129988-66-5P 129988-67-6P 129988-68-7P  
 129988-69-8P 129988-70-1P 129988-71-2P  
 129988-72-3P 129988-73-4P 129988-74-5P  
 129988-75-6P 129988-76-7P 129988-77-8P  
 129988-78-9P 129988-79-0P 129988-80-3P  
 129988-81-4P 129988-82-5P 129988-83-6P  
 129988-84-7P 129988-85-8P 129988-86-9P  
 129988-87-0P 129988-88-1P 129988-89-2P  
 129988-90-5P 129988-91-6P 129988-92-7P  
 129988-93-8P 129988-94-9P 129988-95-0P  
 129988-96-1P 129988-97-2P 129988-98-3P  
 129988-99-4P 129989-00-0P 129989-01-1P  
 129989-02-2P 129989-03-3P 129989-04-4P  
 129989-05-5P 129989-06-6P 129989-07-7P  
 129989-08-8P 129989-09-9P 129989-10-2P  
 129989-11-3P 130014-55-0P 130014-56-1P  
 130014-57-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as gastrointestinal agent)

RN 129988-57-4 CAPLUS

CN Imidazo[1,2-a]pyridine-3-methanol, 8-[(2-(acetyloxy)-2,3-dihydro-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-58-5 CAPLUS

CN Imidazo[1,2-a]pyridine-3-methanol, 8-[(2,3-dihydro-2-[(4-methoxyphenyl)methoxy]-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-59-6 CAPLUS

CN Imidazo[1,2-a]pyridine-3-methanol, 8-[(2,3-dihydro-2-[(3,4,5-trimethoxyphenyl)methoxy]-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-60-9 CAPLUS

CN Acetic acid, methoxy-, 5-fluoro-2,3-dihydro-1-[(3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 129988-61-0 CAPLUS

CN Cyclopropanecarboxylic acid, 2,3-dihydro-1-[(3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-1H-inden-2-yl ester, trans- (9CI)

(CA INDEX NAME)


Relative stereochemistry.



RN 129988-62-1 CAPLUS

CN Benzeneacetic acid, 2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-63-2 CAPLUS

CN 2-Furancarboxylic acid, 2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-64-3 CAPLUS

CN Carbamic acid, dimethyl-, 2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-65-4 CAPLUS

CN Imidazo[1,2-a]pyridine-3-methanol, 8-[[2-[(aminocarbonyl)oxy]-2,3-dihydro-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-66-5 CAPLUS

CN Carbamic acid, (2-hydroxyethyl)-, 2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-67-6 CAPLUS

CN Carbamic acid, (1,1-dimethylethyl)-, 2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-68-7 CAPLUS

CN Carbamic acid, (2-hydroxyethyl)methyl-, 2,3-dihydro-1-[(3-hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-69-8 CAPLUS

CN Imidazo[1,2-a]pyridine-3-methanol, 8-[(2,3-dihydro-2-methoxy-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-70-1 CAPLUS

CN Imidazo[1,2-a]pyridine-3-methanol, 8-[(2-(benzoyloxy)-2,3-dihydro-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-71-2 CAPLUS

CN Benzoic acid, 3-methoxy-, 2,3-dihydro-1-[(3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-1H-inden-2-yl ester, trans- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 129988-72-3 CAPLUS

CN Benzoic acid, 2-methoxy-, 2,3-dihydro-1-[(3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-1H-inden-2-yl ester, trans- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 129988-73-4 CAPLUS

CN Benzoic acid, 3,4-dimethoxy-, 2,3-dihydro-1-[(3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-1H-inden-2-yl ester, trans- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 129988-74-5 CAPLUS

CN Imidazo[1,2-a]pyridine-3-methanol, 8-[[2,3-dihydro-2-[(phenylamino)carbonyl]oxy]-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 129988-75-6 CAPLUS

CN 4-Morpholinecarboxylic acid, 2,3-dihydro-1-[(3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-1H-inden-2-yl ester, trans- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 129988-76-7 CAPLUS

CN Carbamic acid, (4-methoxyphenyl)-, 2,3-dihydro-1-[(3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-1H-inden-2-yl ester, trans- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 129988-77-8 CAPLUS


CN Acetic acid, methoxy-, 2,3-dihydro-1-[(3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 129988-78-9 CAPLUS

CN Propanoic acid, 2-methoxy-, 2,3-dihydro-1-[(3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-1H-inden-2-yl ester (9CI) (CA INDEX NAME)



RN 129988-79-0 CAPLUS


CN Propanoic acid, 2-methoxy-, 5-fluoro-2,3-dihydro-1-[(3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-1H-inden-2-yl ester (9CI) (CA INDEX NAME)



RN 129988-80-3 CAPLUS

CN Carbonic acid, 2,3-dihydro-1-[(3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-1H-inden-2-yl methyl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-81-4 CAPLUS

CN Acetic acid, (2-methoxyethoxy)-, 2,3-dihydro-1-[(3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-82-5 CAPLUS

CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[[2-(acetyloxy)-2,3-dihydro-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-83-6 CAPLUS

CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[[2-(benzoyloxy)-2,3-dihydro-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-84-7 CAPLUS

CN Benzoic acid, 4-methoxy-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-85-8 CAPLUS

CN Cyclopropanecarboxylic acid, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-86-9 CAPLUS

CN Benzeneacetic acid, 1-[ (3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-87-0 CAPLUS

CN 2-Furancarboxylic acid, 1-[ (3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-88-1 CAPLUS

CN Benzoic acid, 3,4,5-trimethoxy-, 1-[ (3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-89-2 CAPLUS

CN Benzoic acid, 3-methoxy-, 1-[ (3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-90-5 CAPLUS

CN Benzoic acid, 2-methoxy-, 1-[ (3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-91-6 CAPLUS

CN Benzoic acid, 2,6-dimethoxy-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-92-7 CAPLUS

CN Acetic acid, methoxy-, 5-fluoro-1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-93-8 CAPLUS

CN Acetic acid, methoxy-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-94-9 CAPLUS


CN Acetic acid, methoxy-, 1-[(3-cyano-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 129988-95-0 CAPLUS

CN Propanoic acid, 2-methoxy-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)



RN 129988-96-1 CAPLUS


CN Propanoic acid, 2-methoxy-, 5-fluoro-1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)



RN 129988-97-2 CAPLUS

CN Acetic acid, (2-methoxyethoxy)-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-98-3 CAPLUS

CN Carbonic acid, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl methyl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129988-99-4 CAPLUS

CN Imidazo[1,2-a]pyridine-2-carboxaldehyde, 8-[(2,3-dihydro-2-methoxy-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129989-00-0 CAPLUS

CN Carbamic acid, dimethyl-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129989-01-1 CAPLUS

CN 4-Morpholinecarboxylic acid, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129989-02-2 CAPLUS

CN Carbamic acid, (2-hydroxyethyl)-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129989-03-3 CAPLUS

CN Carbamic acid, (2-hydroxyethyl)methyl-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129989-04-4 CAPLUS

CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[[2-[(aminocarbonyl)oxy]-2,3-dihydro-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129989-05-5 CAPLUS

CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[[2,3-dihydro-2-[(phenylamino)carbonyl]oxy]-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129989-06-6 CAPLUS

CN Carbamic acid, (2,4-dimethoxyphenyl)-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129989-07-7 CAPLUS

CN Carbamic acid, (1,1-dimethylethyl)-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129989-08-8 CAPLUS

CN Imidazo[1,2-a]pyridine-3-methanol, 8-[[5-fluoro-2,3-dihydro-2-(phenylmethoxy)-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129989-09-9 CAPLUS

CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[[5-fluoro-2,3-dihydro-2-(phenylmethoxy)-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129989-10-2 CAPLUS

CN Benzoic acid, 4-methoxy-, 5-fluoro-1-[ (3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 129989-11-3 CAPLUS

CN Benzoic acid, 4-methoxy-, 5-fluoro-2,3-dihydro-1-[ [3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 130014-55-0 CAPLUS

CN Imidazo[1,2-a]pyridine-3-methanol, 8-[[2-[(2,6-dimethoxyphenyl)methoxy]-2,3-dihydro-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 130014-56-1 CAPLUS

CN Carbamic acid, (2,4-dimethoxyphenyl)-, 2,3-dihydro-1-[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 130014-57-2 CAPLUS

CN Benzoic acid, 3,4-dimethoxy-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1989:423515 CAPLUS

DOCUMENT NUMBER: 111:23515

TITLE: Diazoles, their preparation, and their use in treating  
 gastrointestinal disorders  
 INVENTOR(S): Senn-Bilfinger, Joerg; Grundler, Gerhard; Schaefer,  
 Hartmann; Klemm, Kurt; Rainer, Georg; Schudt,  
 Christian; Simon, Wolfgang Alexander; Riedel, Richard;  
 Postius, Stefan  
 PATENT ASSIGNEE(S): Byk-Gulden Lomberg Chemische Fabrik G.m.b.H., Fed.  
 Rep. Ger.  
 SOURCE: Eur. Pat. Appl., 29 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 299470	A1	19890118	EP 1988-111302	19880714
EP 299470	B1	19961204		
R: ES, GR				
WO 8900570	A1	19890126	WO 1988-EP638	19880714
W: AU, DK, FI, HU, JP, KR, NO, US				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
AU 8821261	A1	19890213	AU 1988-21261	19880714
AU 615666	B2	19911010		
EP 370056	A1	19900530	EP 1988-907054	19880714
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
HU 52097	A2	19900628	HU 1988-4838	19880714
HU 204828	B	19920228		
JP 02504271	T2	19901206	JP 1988-506300	19880714
CA 1327796	A1	19940315	CA 1988-572025	19880714
AT 145907	E	19961215	AT 1988-111302	19880714
ZA 8805129	A	19890222	ZA 1988-5129	19880715
IL 87118	A1	19930131	IL 1988-87118	19880715
CN 1031842	A	19890322	CN 1988-106089	19880716
DK 9000121	A	19900115	DK 1990-121	19900115
NO 9000202	A	19900115	NO 1990-202	19900115
US 5112834	A	19920512	US 1990-445611	19900116
PRIORITY APPLN. INFO.:			CH 1987-2709	A 19870716
			CH 1988-390	A 19880204
			WO 1988-EP638	A 19880714

OTHER SOURCE(S): MARPAT 111:23515

GI For diagram(s), see printed CA Issue.


AB Diazoles [I; R1 = H, halo; R2 = H, C1-4 alkyl, hydroxy-, halo-, cyano-C1-4-alkyl, C1-4 alkoxy carbonyl; R3 = H, (un)substituted C1-4 alkyl, NO, NO<sub>2</sub>, (di)(C1-4 alkyl)amino, C1-4 alkoxy carbonyl; R4, R5 = H, C1-4 alkyl, alkoxy, halo, CF<sub>3</sub>; R6 = H, C1-4 alkyl; n = 1,2; G1 = CH, N; G2 = O, NH, C1-4 alkylimino, C1-4 alkylene; G3 = hydroxy-C3-5-alkylene; G4 = S, O, CH:CH] and their salts, useful in treating gastrointestinal disorders, were prepared 8-Amino-2-methylimidazo[1,2-a]pyridine in Et<sub>2</sub>O was treated with Al<sub>2</sub>O<sub>3</sub> and the mixture stirred 30 min at room temperature, treated with indene

1,2-oxide, and stirred 2-48 h at room temperature to give 8-(2-trans-hydroxy-2,3-dihydro-1-indenylamino)-2-methylindiazolo[1,2-a]pyridine (II). The 3-Me derivative of II, at 0.3 μmol/kg intraduodenally reduced the lesion index of the stomach of rats 25% after acetylsalicylic acid ulcer provocation and decreased HCl secretion 4.0-27%.

IT 121082-21-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and reaction of, in synthesis of imidazopyridine  
 gastrointestinal tract protective agent)

RN 121082-21-1 CAPLUS  
CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[[2,3-dihydro-2-[(methylsulfonyl)oxy]-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 121081-87-6P 121081-88-7P 121081-89-8P  
121081-90-1P 121081-91-2P 121081-92-3P  
121081-93-4P 121081-94-5P 121081-95-6P  
121081-96-7P 121081-97-8P 121081-98-9P  
121081-99-0P 121082-00-6P 121082-03-9P  
121082-04-0P 121082-05-1P 121082-06-2P  
121082-07-3P 121082-08-4P 121082-09-5P  
121082-10-8P 121082-11-9P 121082-12-0P  
121082-13-1P 121082-14-2P 121098-83-7P  
121098-84-8P 121098-85-9P 121154-38-9P  
121154-39-0P 121154-40-3P 121154-41-4P  
121154-42-5P 121154-43-6P 121154-44-7P  
121154-45-8P 121154-46-9P 121155-44-0P  
121209-15-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as gastrointestinal tract protective agent)


RN 121081-87-6 CAPLUS  
CN 1H-Inden-2-ol, 2,3-dihydro-1-[(2-methylimidazo[1,2-a]pyridin-8-yl)amino]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121081-88-7 CAPLUS  
CN 1H-Inden-2-ol, 1-[(2,3-dimethylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121081-89-8 CAPLUS

CN 1H-Inden-2-ol, 2,3-dihydro-1-[(2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121081-90-1 CAPLUS

CN Imidazo[1,2-a]pyridine-3-acetonitrile, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121081-91-2 CAPLUS

CN 2-Naphthalenol, 1-[(2,3-dimethylimidazo[1,2-a]pyridin-8-yl)oxy]-1,2,3,4-tetrahydro-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121081-92-3 CAPLUS

CN Imidazo[1,2-a]pyridine-3-acetonitrile, 2-methyl-8-[(1,2,3,4-tetrahydro-2-hydroxy-1-naphthalenyl)oxy]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121081-93-4 CAPLUS

CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121081-94-5 CAPLUS

CN Imidazo[1,2-a]pyridine-3-methanol, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121081-95-6 CAPLUS

CN 1H-Inden-2-ol, 2,3-dihydro-1-[(2-methyl-3-nitrosoimidazo[1,2-a]pyridin-8-yl)oxy]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121081-96-7 CAPLUS

CN 1H-Inden-2-ol, 1-[(3-amino-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● x HCl

RN 121081-97-8 CAPLUS

CN 2-Naphthalenol, 1,2,3,4-tetrahydro-1-[(2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121081-98-9 CAPLUS

CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 2-methyl-8-[(1,2,3,4-tetrahydro-2-hydroxy-1-naphthalenyl)oxy]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121081-99-0 CAPLUS

CN Imidazo[1,2-a]pyridine-3-methanol, 2-methyl-8-[(1,2,3,4-tetrahydro-2-hydroxy-1-naphthalenyl)oxy]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121082-00-6 CAPLUS

CN 2-Naphthalenol, 1,2,3,4-tetrahydro-1-[(2-methyl-3-nitrosoimidazo[1,2-a]pyridin-8-yl)oxy]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121082-03-9 CAPLUS

CN Imidazo[1,2-a]pyridine-3-methanol, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)amino]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121082-04-0 CAPLUS

CN 2-Naphthalenol, 1-[(3-amino-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-1,2,3,4-tetrahydro-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● x HCl

RN 121082-05-1 CAPLUS

CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 6-chloro-8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121082-06-2 CAPLUS

CN Imidazo[1,2-a]pyridine-3-methanol, 6-chloro-8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121082-07-3 CAPLUS

CN 1H-Inden-2-ol, 1-[(6-chloro-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121082-08-4 CAPLUS

CN 1H-Inden-2-ol, 1-[(3-amino-6-chloro-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121082-09-5 CAPLUS

CN Imidazo[1,2-a]pyridine-3-methanol, 8-[(5-fluoro-2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121082-10-8 CAPLUS

CN 1H-Inden-2-ol, 5-fluoro-2,3-dihydro-1-[(2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121082-11-9 CAPLUS

CN 1H-Inden-2-ol, 5-fluoro-2,3-dihydro-1-[(2-methyl-3-nitrosoimidazo[1,2-a]pyridin-8-yl)oxy]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121082-12-0 CAPLUS

CN 1H-Inden-2-ol, 1-[3-amino-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-5-fluoro-2,3-dihydro-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● x HCl

RN 121082-13-1 CAPLUS

CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121082-14-2 CAPLUS

CN Imidazo[1,2-a]pyridine-3-methanol, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121098-83-7 CAPLUS

CN 1H-Inden-2-ol, 1-[(3-amino-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121098-84-8 CAPLUS

CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)amino]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121098-85-9 CAPLUS

CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[(5-fluoro-2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121154-38-9 CAPLUS

CN Imidazo[1,2-a]pyridine-3-methanol, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, (1R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 121154-39-0 CAPLUS

CN Imidazo[1,2-a]pyridine-3-acetonitrile, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, (1R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 121154-40-3 CAPLUS

CN 1H-Inden-2-ol, 2,3-dihydro-1-[(2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-, (1R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 121154-41-4 CAPLUS

CN 1H-Inden-2-ol, 2,3-dihydro-1-[(2-methyl-3-nitrosoimidazo[1,2-a]pyridin-8-yl)oxy]-, (1R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 121154-42-5 CAPLUS

CN 1H-Inden-2-ol, 1-[(3-amino-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-, hydrochloride, (1R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 121154-43-6 CAPLUS

CN Imidazo[1,2-a]pyridine-3-acetonitrile, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, (1S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 121154-44-7 CAPLUS

CN Imidazo[1,2-a]pyridine-3-methanol, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, (1S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 121154-45-8 CAPLUS

CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 2-methyl-8-[(1,2,3,4-tetrahydro-2-hydroxy-1-naphthalenyl)oxy]-, (1S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 121154-46-9 CAPLUS

CN Imidazo[1,2-a]pyridine-3-methanol, 2-methyl-8-[(1,2,3,4-tetrahydro-2-hydroxy-1-naphthalenyl)oxy]-, (1S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 121155-44-0 CAPLUS

CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, (1R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 121209-15-2 CAPLUS

CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, (1S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 121082-30-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as intermediate for gastrointestinal tract protective agent)

RN 121082-30-2 CAPLUS

CN 1H-Inden-2-ol, 2,3-dihydro-1-[(2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-, methanesulfonate (ester), trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 121081-89-8 121082-19-7

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of, in synthesis of imidazopyridine gastrointestinal tract protective agent)

RN 121081-89-8 CAPLUS

CN 1H-Inden-2-ol, 2,3-dihydro-1-[(2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121082-19-7 CAPLUS

CN 1H-Inden-2-ol, 1-[(6-chloro-2-methyl-3-nitroimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1989:154298 CAPLUS

DOCUMENT NUMBER: 110:154298


TITLE: Substituted imidazo[1,2-a]pyridines and -pyrazines useful as ulcer inhibitors, drugs containing them, and processes for their preparation

INVENTOR(S): Senn-Bilfinger, Joerg; Grundler, Gerhard; Schaefer,

PATENT ASSIGNEE(S): Hartmann; Klemm, Kurt; Rainer, Georg; Riedel, Richard;  
 Schudt, Christian; Simon, Wolfgang  
 Byk Gulden Lomberg Chemische Fabrik G.m.b.H., Fed.  
 Rep. Ger.  
 SOURCE: Eur. Pat. Appl., 21 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 290003	A2	19881109	EP 1988-107138	19880504
EP 290003	A3	19881228		
R: ES, GR				
WO 8808843	A2	19881117	WO 1988-EP368	19880504
WO 8808843	A3	19881201		
W: AU, DK, FI, HU, JP, KR, NO, US				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
AU 8816860	A1	19881206	AU 1988-16860	19880504
ZA 8803169	A	19881228	ZA 1988-3169	19880504
PRIORITY APPLN. INFO.:			CH 1987-1771	A 19870508
			WO 1988-EP368	A 19880504

OTHER SOURCE(S): MARPAT 110:154298  
GI



AB The title compds. [I; R1 = H, halo, C1-4 alkyl, alkoxy, alkoxycarbonyl, cyano; R2 = H, C1-4 alkyl, hydroxyalkyl, haloalkyl, cyanoalkyl, alkoxycarbonyl; R3 = R2, CHO, C1-4 aminoalkyl, NO, NO<sub>2</sub>, amino; R4, R5 = H, C1-4 alkyl, alkoxy, halo, CF<sub>3</sub>; R6 = H, C1-4 alkyl; X1 = CH, N; X2 = O, imino, S, CH, C1-4 alkylene; X3 = (CH<sub>2</sub>)<sub>n</sub> (n = 2-5), CH:CHCH<sub>2</sub>, CH:CHCH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>CH:CHCH<sub>2</sub>; X4 = S, O, CH:CH], useful as ulcer inhibitors, were prepared NaH was added to 8-hydroxy-2,3-dimethylimidazo[1,2-a]pyridine in DMF and the mixture was stirred 30 min at room temperature 1-Chloroindane was then added

and the mixture was stirred 4 h at 50° to give 8-(2,3-dihydro-1-indenyl)-2,3-dimethylimidazo[1,2-a]pyridine. The latter at 3.0 μmol/kg i.v. in rats gave 62% inhibition of stomach acid secretion and 100% inhibition of aspirin-induced ulcers.


IT 119858-29-6P 119858-30-9P 119858-31-0P  
 119858-32-1P 119858-33-2P 119858-36-5P  
 119858-38-7P 119858-48-9P 119858-50-3P  
 119885-10-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of, as ulcer inhibitor)


RN 119858-29-6 CAPLUS

CN Imidazo[1,2-a]pyridine, 8-[(2,3-dihydro-1H-inden-1-yl)oxy]-2,3-dimethyl-  
(9CI) (CA INDEX NAME)



RN 119858-30-9 CAPLUS


CN Imidazo[1,2-a]pyridinium, 8-[(2,3-dihydro-1H-inden-1-yl)oxy]-1,2,3-trimethyl-, iodide (9CI) (CA INDEX NAME)



● I<sup>-</sup>

RN 119858-31-0 CAPLUS


CN Imidazo[1,2-a]pyridine, 2,3-dimethyl-8-[(1,2,3,4-tetrahydro-1-naphthalenyl)oxy]- (9CI) (CA INDEX NAME)



RN 119858-32-1 CAPLUS


CN Imidazo[1,2-a]pyridine-3-acetonitrile, 8-[(2,3-dihydro-1H-inden-1-yl)oxy]-

2-methyl- (9CI) (CA INDEX NAME)




RN 119858-33-2 CAPLUS

CN Imidazo[1,2-a]pyridine, 8-[(2,3-dihydro-1H-inden-1-yl)oxy]-2-methyl- (9CI)  
(CA INDEX NAME)




RN 119858-36-5 CAPLUS

CN Imidazo[1,2-a]pyridin-8-amine, N-(2,3-dihydro-1H-inden-1-yl)-2,3-dimethyl-  
(9CI) (CA INDEX NAME)




RN 119858-38-7 CAPLUS

CN Imidazo[1,2-a]pyridin-8-amine, N-(2,3-dihydro-1H-inden-1-yl)-2-methyl-  
(9CI) (CA INDEX NAME)




RN 119858-48-9 CAPLUS

CN Imidazo[1,2-a]pyridine-3-methanol, 8-[(2,3-dihydro-1H-inden-1-yl)oxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 119858-50-3 CAPLUS

CN Imidazo[1,2-a]pyridine-3-methanol, 8-[(2,3-dihydro-1H-inden-1-yl)amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 119885-10-8 CAPLUS


CN Imidazo[1,2-a]pyridin-8-amine, 2-methyl-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1987:138443 CAPLUS  
 DOCUMENT NUMBER: 106:138443  
 TITLE: Imidazopyridines and -pyrazines as antiulcer agents  
 INVENTOR(S): Ueda, Ikuo; Shiokawa, Youichi; Take, Kazuhiko; Itani, Hiromichi  
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
 SOURCE: Eur. Pat. Appl., 72 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 204285	A1	19861210	EP 1986-107418	19860602
EP 204285	B1	19920115		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
ZA 8603805	A	19870429	ZA 1986-3805	19860521
US 4725601	A	19880216	US 1986-865331	19860521
FI 8602210	A	19861205	FI 1986-2210	19860526
DK 8602503	A	19861205	DK 1986-2503	19860528
CA 1257264	A1	19890711	CA 1986-510496	19860530
JP 62016483	A2	19870124	JP 1986-128941	19860602
AT 71625	E	19920215	AT 1986-107418	19860602
NO 8602208	A	19861205	NO 1986-2208	19860603
HU 40798	A2	19870227	HU 1986-2332	19860603
CN 86104313	A	19870304	CN 1986-104313	19860603
ES 555653	A1	19871201	ES 1986-555653	19860603
AU 8658345	A1	19861211	AU 1986-58345	19860604
AU 593802	B2	19900222		
US 4782055	A	19881101	US 1986-942379	19861216
PRIORITY APPLN. INFO.:			GB 1985-14080	A 19850604
			GB 1985-30878	A 19851216
			US 1986-865331	A2 19860521
			EP 1986-107418	A 19860602
			GB 1986-27736	A 19861120

OTHER SOURCE(S): CASREACT 106:138443; MARPAT 106:138443  
 GI



I



II


AB The title compds. [I; R1 = alkenyl, alkynyl, alkadienyl, alkenyloxyalkyl, alkynyloxyalkyl (protected) carboxyalkynyl, alkenyloxyalkyl; R2 = H, alkyl, aryl; R3 = (substituted) aralkyl; X = O, NH; Y = CH, N] were prepared as antiulcer agents. Thus, (benzyloxy)pyridinamine II cyclocondensed with ClCH<sub>2</sub>COMe to give I (R1 = H, R2 = Me, R3 = 2-ClC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, X = O, Y = CH). This was condensed with HCHO and Me<sub>2</sub>NH, followed by methylation and treatment with HC.tplbond.CCH<sub>2</sub>OH, to give I (R1 = CH<sub>2</sub>OCH<sub>2</sub>C.tplbond.CH, R2 = Me, R3 = 2-ClC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, X = O, Y = CH) (III). In rats 32 mg III/kg orally gave 98.2% inhibition of EtOH-induced ulcers and 100% inhibition of stress-induced ulcers.

IT 107230-22-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of, as antiulcer agent)

RN 107230-22-8 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-methyl-3-(2-propynyl)-8-[(1,2,3,4-tetrahydro-1-naphthalenyl)oxy]- (9CI) (CA INDEX NAME)



=&gt; d his

(FILE 'HOME' ENTERED AT 09:38:46 ON 12 SEP 2006)

FILE 'REGISTRY' ENTERED AT 09:39:08 ON 12 SEP 2006

L1 STRUCTURE UPLOADED

L2 4 S L1

L3 131 S L1 FULL

FILE 'CAPLUS' ENTERED AT 09:39:42 ON 12 SEP 2006

L4 5 S L3 FULL

=&gt; log y

COST IN U.S. DOLLARS

SINCE FILE  
ENTRYTOTAL  
SESSION

FULL ESTIMATED COST

26.47

193.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

CA SUBSCRIBER PRICE

ENTRY	SESSION
-3.75	-3.75

STN INTERNATIONAL LOGOFF AT 09:40:51 ON 12 SEP 2006